Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 11

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 11
---
| 3. | FOR the Equity Plan Increase Proposal; |

| 4. | FOR the Non-Binding Advisory Vote on Golden Parachutes Proposal; and |

| 5. | FOR the Adjournment Proposal. |

Who can vote at the Special Meeting? Only stockholders of record at the close of business on the Record Date of January 30, 2025 are entitled to vote at the Special Meeting. As of January 30, 2025, there were 24,696,568 shares of our common stock issued and outstanding. Each share of common stock is entitled to one vote on each matter properly brought before the Special Meeting. Where and when is the Special Meeting? The Special Meeting is scheduled to be held online on February 28, 2025at 10:00 am Pacific Time. You will be able to attend the Special Meeting virtually by visiting www.virtualshareholdermeeting.com/AADI2025SM, where you will be able to listen to the Special Meeting live, submit questions and vote online by entering the control number on your proxy card or voter instruction form. We encourage you to complete your registration as soon as possible if you desire to attend the Special Meeting. If you encounter any difficulties accessing the virtual Special Meeting, please contact technical support by following the instructions provided to you upon registration for the Special Meeting. What is the Divestiture? The Divestiture is the sale of 100% of the outstanding shares of capital stock of Aadi Sub from Aadi to Kaken and thereby all or substantially all of Aadi’s assets related to its FYARRO Business, pursuant to the terms of the Divestiture Agreement. Kaken will also acquire all rights to the “Aadi” name and trademark under the terms of the Divestiture Agreement. The Divestiture may be deemed to be a sale of substantially all of Aadi’s assets under Section 271 of the DGCL. The transaction is expected to close in the first half of 2025, subject to Aadi stockholder approval and certain closing conditions. Why am I being asked to vote on the Divestiture? The Divestiture may constitute the sale of substantially all of the assets of Aadi under Section 271 of the DGCL. We are seeking the approval of Aadi stockholders for the Divestiture because the question of whether the Divestiture constitutes the sale of substantially all of the assets of Aadi under the DGCL is highly fact-specific, and because Aadi’s board of directors considered the